Latest news with #CDMOs
Yahoo
2 days ago
- Business
- Yahoo
Pharmaceutical Membrane Filtration Strategic Business Report 2025-2030 - Continuous Process Optimization Generates Demand, Expanding Biologics Strengthens Business Case for High-Precision Filtration
The global Pharmaceutical Membrane Filtration market, valued at $10.8 billion in 2024, is expected to reach $19.6 billion by 2030, growing at a 10.5% CAGR. Key drivers include rising biopharmaceutical demand, chronic disease prevalence, and advanced drug formulations. Regulatory requirements and technological advancements like continuous manufacturing and sustainable practices are reshaping the landscape. This report offers detailed insights into market growth, trends, and key players, helping businesses navigate this evolving sector effectively. Pharmaceutical Membrane Filtration Market Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Pharmaceutical Membrane Filtration - Global Strategic Business Report" report has been added to global market for Pharmaceutical Membrane Filtration was valued at US$10.8 Billion in 2024 and is projected to reach US$19.6 Billion by 2030, growing at a CAGR of 10.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business membrane filtration plays a pivotal yet often overlooked role in drug manufacturing, serving as a crucial mechanism for purifying and sterilizing various substances. But what makes this process indispensable to the industry? The stringent requirements in pharmaceutical production demand that all injectable drugs and intravenous solutions are completely free from contaminants, including microorganisms and particulates. Membrane filtration is uniquely equipped to meet these standards, removing unwanted particles without altering the essential properties of the drug. The growth in the pharmaceutical membrane filtration market is driven by several factors, including the expanding demand for biopharmaceuticals, the rising prevalence of chronic diseases, and the need for sophisticated drug formulations. Biologics and biosimilars, which require highly precise and sensitive filtration processes, are increasingly dominating the pharmaceutical market. This, in turn, is spurring the demand for advanced filtration technologies that can ensure the purity and effectiveness of these complex therapies. The trend towards outsourcing pharmaceutical production to CDMOs is also a significant growth driver, as these organizations seek scalable and dependable filtration solutions to meet the diverse needs of their clients. Additionally, recent global health events have heightened awareness of the importance of sterility in drug production, prompting pharmaceutical companies to invest heavily in cutting-edge filtration systems. Finally, the increasing focus on stringent quality controls and regulatory compliance is pushing companies to adopt advanced filtration technologies that can guarantee the safety and effectiveness of their Role Do Regulations Play in Shaping Pharmaceutical Filtration Practices?Pharmaceutical membrane filtration is tightly interwoven with regulatory compliance, which is at the core of pharmaceutical manufacturing. Regulatory bodies such as the FDA, EMA, and WHO impose strict guidelines that require drugs, particularly those administered via injection, to be free from contaminants, including microbial entities and pyrogens. As these guidelines become more stringent, the demand for reliable and efficient membrane filtration systems continues to grow. The industry is witnessing a surge in the adoption of single-use filtration systems, which reduce contamination risks and meet evolving regulatory requirements. Additionally, globalization has further complicated compliance, with pharmaceutical companies now required to meet various international standards. Membrane filtration systems have become indispensable tools, ensuring that products meet these increasingly complex regulations and quality controls across multiple Are Technological Advancements Shaping the Future of Filtration?Technological innovation is revolutionizing pharmaceutical membrane filtration, driving new trends that are shaping the future of drug manufacturing. A key trend is the transition towards continuous manufacturing, which requires filtration systems capable of operating without interruption, thereby increasing efficiency and reducing costs. Advances in membrane materials, such as the integration of nanotechnology and new polymers, are improving the performance and durability of filtration systems, ensuring that they can handle the increased demands of modern pharmaceutical processes. Sustainability is another growing focus, as companies seek to adopt environmentally friendly filtration technologies that reduce waste and energy consumption. Furthermore, the rise of personalized medicine is influencing the industry, as the production of specialized drugs for smaller patient populations demands highly precise filtration processes to maintain quality and ScopeReport Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as 3M Company, Alfa Laval, Amazon Filters Ltd., Danaher, Donaldson Company and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the Filters segment, which is expected to reach US$11.7 Billion by 2030 with a CAGR of a 9.9%. The Systems segment is also set to grow at 12.8% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $2.8 Billion in 2024, and China, forecasted to grow at an impressive 14.0% CAGR to reach $4.5 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Segments Product Type (Filters, Systems, Accessories) Technique (Microfiltration, Reverse Osmosis, Ultrafiltration, Nanofiltration, Other Techniques) Application (Final Product Processing, Raw Material Filtration, Cell Separation, Water Purification, Air Purification) Tariff Impact Analysis: Key Insights for 2025What's Included in This Edition: Tariff-adjusted market forecasts by region and segment Analysis of cost and supply chain implications by sourcing and trade exposure Strategic insights into geographic shifts Buyers receive a free July 2025 update with: Finalized tariff impacts and new trade agreement effects Updated projections reflecting global sourcing and cost shifts Expanded country-specific coverage across the industry Key Attributes: Report Attribute Details No. of Pages 93 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $10.8 Billion Forecasted Market Value (USD) by 2030 $19.6 Billion Compound Annual Growth Rate 10.5% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights Tariff Impact on Global Supply Chain Patterns Global Economic Update Pharmaceutical Membrane Filtration - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Rising Demand for Biopharmaceuticals Spurs Growth in Membrane Filtration Market Continuous Manufacturing Throws the Spotlight on Advanced Filtration Systems Expanding Biologics Market Strengthens Business Case for High-Precision Filtration Single-Use Filtration Systems Propel Market Growth Regulatory Scrutiny Drives Adoption of Advanced Sterile Filtration Technologies Chronic Disease Prevalence Expands Addressable Market Opportunity Nanotechnology Innovations Accelerate Demand for Next-Generation Membranes Globalization of Pharmaceutical Supply Chains Spurs Need for Scalable Filtration Personalized Medicine Trends Generate Demand for Custom Filtration Solutions Sustainability Concerns Drive Adoption of Eco-Friendly Filtration Technologies R&D Investments Propel Market Expansion Energy-Efficient Filtration Systems Strengthen the Case for Green Manufacturing Practices Increased Focus on Biosimilars Propels the Adoption of Advanced Filtration Solutions Continuous Process Optimization Generates Market Demand FOCUS ON SELECT PLAYERS 3M Company Alfa Laval Amazon Filters Ltd. Danaher Donaldson Company Eaton Corporation GE Healthcare GEA Group Graver Technologies Koch Membrane Systems Meissner Filtration Products Merck Millipore Novasep Parker Hannifin Porvair Plc. Repligen Corporation Sartorius Stedim Biotech Sterlitech Corporation Synder Corporation Thermo Fisher Scientific For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Pharmaceutical Membrane Filtration Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Pharmaceutical Membrane Filtration Strategic Business Report 2025-2030 - Continuous Process Optimization Generates Demand, Expanding Biologics Strengthens Business Case for High-Precision Filtration
The global Pharmaceutical Membrane Filtration market, valued at $10.8 billion in 2024, is expected to reach $19.6 billion by 2030, growing at a 10.5% CAGR. Key drivers include rising biopharmaceutical demand, chronic disease prevalence, and advanced drug formulations. Regulatory requirements and technological advancements like continuous manufacturing and sustainable practices are reshaping the landscape. This report offers detailed insights into market growth, trends, and key players, helping businesses navigate this evolving sector effectively. Pharmaceutical Membrane Filtration Market Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Pharmaceutical Membrane Filtration - Global Strategic Business Report" report has been added to global market for Pharmaceutical Membrane Filtration was valued at US$10.8 Billion in 2024 and is projected to reach US$19.6 Billion by 2030, growing at a CAGR of 10.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business membrane filtration plays a pivotal yet often overlooked role in drug manufacturing, serving as a crucial mechanism for purifying and sterilizing various substances. But what makes this process indispensable to the industry? The stringent requirements in pharmaceutical production demand that all injectable drugs and intravenous solutions are completely free from contaminants, including microorganisms and particulates. Membrane filtration is uniquely equipped to meet these standards, removing unwanted particles without altering the essential properties of the drug. The growth in the pharmaceutical membrane filtration market is driven by several factors, including the expanding demand for biopharmaceuticals, the rising prevalence of chronic diseases, and the need for sophisticated drug formulations. Biologics and biosimilars, which require highly precise and sensitive filtration processes, are increasingly dominating the pharmaceutical market. This, in turn, is spurring the demand for advanced filtration technologies that can ensure the purity and effectiveness of these complex therapies. The trend towards outsourcing pharmaceutical production to CDMOs is also a significant growth driver, as these organizations seek scalable and dependable filtration solutions to meet the diverse needs of their clients. Additionally, recent global health events have heightened awareness of the importance of sterility in drug production, prompting pharmaceutical companies to invest heavily in cutting-edge filtration systems. Finally, the increasing focus on stringent quality controls and regulatory compliance is pushing companies to adopt advanced filtration technologies that can guarantee the safety and effectiveness of their Role Do Regulations Play in Shaping Pharmaceutical Filtration Practices?Pharmaceutical membrane filtration is tightly interwoven with regulatory compliance, which is at the core of pharmaceutical manufacturing. Regulatory bodies such as the FDA, EMA, and WHO impose strict guidelines that require drugs, particularly those administered via injection, to be free from contaminants, including microbial entities and pyrogens. As these guidelines become more stringent, the demand for reliable and efficient membrane filtration systems continues to grow. The industry is witnessing a surge in the adoption of single-use filtration systems, which reduce contamination risks and meet evolving regulatory requirements. Additionally, globalization has further complicated compliance, with pharmaceutical companies now required to meet various international standards. Membrane filtration systems have become indispensable tools, ensuring that products meet these increasingly complex regulations and quality controls across multiple Are Technological Advancements Shaping the Future of Filtration?Technological innovation is revolutionizing pharmaceutical membrane filtration, driving new trends that are shaping the future of drug manufacturing. A key trend is the transition towards continuous manufacturing, which requires filtration systems capable of operating without interruption, thereby increasing efficiency and reducing costs. Advances in membrane materials, such as the integration of nanotechnology and new polymers, are improving the performance and durability of filtration systems, ensuring that they can handle the increased demands of modern pharmaceutical processes. Sustainability is another growing focus, as companies seek to adopt environmentally friendly filtration technologies that reduce waste and energy consumption. Furthermore, the rise of personalized medicine is influencing the industry, as the production of specialized drugs for smaller patient populations demands highly precise filtration processes to maintain quality and ScopeReport Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as 3M Company, Alfa Laval, Amazon Filters Ltd., Danaher, Donaldson Company and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the Filters segment, which is expected to reach US$11.7 Billion by 2030 with a CAGR of a 9.9%. The Systems segment is also set to grow at 12.8% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $2.8 Billion in 2024, and China, forecasted to grow at an impressive 14.0% CAGR to reach $4.5 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Segments Product Type (Filters, Systems, Accessories) Technique (Microfiltration, Reverse Osmosis, Ultrafiltration, Nanofiltration, Other Techniques) Application (Final Product Processing, Raw Material Filtration, Cell Separation, Water Purification, Air Purification) Tariff Impact Analysis: Key Insights for 2025What's Included in This Edition: Tariff-adjusted market forecasts by region and segment Analysis of cost and supply chain implications by sourcing and trade exposure Strategic insights into geographic shifts Buyers receive a free July 2025 update with: Finalized tariff impacts and new trade agreement effects Updated projections reflecting global sourcing and cost shifts Expanded country-specific coverage across the industry Key Attributes: Report Attribute Details No. of Pages 93 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $10.8 Billion Forecasted Market Value (USD) by 2030 $19.6 Billion Compound Annual Growth Rate 10.5% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights Tariff Impact on Global Supply Chain Patterns Global Economic Update Pharmaceutical Membrane Filtration - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Rising Demand for Biopharmaceuticals Spurs Growth in Membrane Filtration Market Continuous Manufacturing Throws the Spotlight on Advanced Filtration Systems Expanding Biologics Market Strengthens Business Case for High-Precision Filtration Single-Use Filtration Systems Propel Market Growth Regulatory Scrutiny Drives Adoption of Advanced Sterile Filtration Technologies Chronic Disease Prevalence Expands Addressable Market Opportunity Nanotechnology Innovations Accelerate Demand for Next-Generation Membranes Globalization of Pharmaceutical Supply Chains Spurs Need for Scalable Filtration Personalized Medicine Trends Generate Demand for Custom Filtration Solutions Sustainability Concerns Drive Adoption of Eco-Friendly Filtration Technologies R&D Investments Propel Market Expansion Energy-Efficient Filtration Systems Strengthen the Case for Green Manufacturing Practices Increased Focus on Biosimilars Propels the Adoption of Advanced Filtration Solutions Continuous Process Optimization Generates Market Demand FOCUS ON SELECT PLAYERS 3M Company Alfa Laval Amazon Filters Ltd. Danaher Donaldson Company Eaton Corporation GE Healthcare GEA Group Graver Technologies Koch Membrane Systems Meissner Filtration Products Merck Millipore Novasep Parker Hannifin Porvair Plc. Repligen Corporation Sartorius Stedim Biotech Sterlitech Corporation Synder Corporation Thermo Fisher Scientific For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Pharmaceutical Membrane Filtration Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
27-05-2025
- Business
- Yahoo
Healthcare CDMO Strategic Research Report 2025: Market to Surpass $350 Billion by 2030 - Rising Outsourcing of Drug Discovery and Early-Stage Development Strengthens Demand
This comprehensive report delves into market trends, drivers, and forecasts. Key growth areas include biologics manufacturing and personalized medicine, with significant contributions from technological advancements like continuous production and digital technologies. Regions like the U.S. and China showcase robust growth, emphasizing the critical role of CDMOs in drug development and manufacturing. Healthcare Contract Development and Manufacturing Organization Market Dublin, May 27, 2025 (GLOBE NEWSWIRE) -- The "Healthcare Contract Development and Manufacturing Organization - Global Strategic Business Report" report has been added to global market for Healthcare Contract Development and Manufacturing Organization was valued at US$351.7 Billion in 2024 and is projected to reach US$547.1 Billion by 2030, growing at a CAGR of 7.6% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Healthcare Contract Development and Manufacturing Organization market. Healthcare Contract Development and Manufacturing Organizations (CDMOs) are critical partners in the pharmaceutical and biotechnology industries, providing outsourced services for drug development, manufacturing, and commercialization. CDMOs offer a range of services, from early-stage drug discovery and development to clinical trials and commercial-scale production. By outsourcing to CDMOs, pharmaceutical companies can reduce costs, accelerate time-to-market, and focus on core competencies such as research and marketing. The rise of biologics, biosimilars, and personalized medicine has further expanded the role of CDMOs, as these complex therapies require specialized manufacturing expertise that many pharmaceutical companies lack in-house. What Factors Are Driving the Growth in the Healthcare CDMO Market?The growth in the healthcare CDMO market is driven by several factors, including the increasing outsourcing of drug development and manufacturing activities by pharmaceutical and biotechnology companies. The rising demand for biologics, biosimilars, and personalized medicine is fueling the need for specialized manufacturing capabilities that CDMOs provide. Additionally, the need for faster time-to-market and cost-effective production solutions is pushing pharmaceutical companies to partner with CDMOs. Technological advancements in bioprocessing and continuous manufacturing are further driving the growth of the CDMO market. Furthermore, regulatory pressures and the complexity of drug development are encouraging pharmaceutical companies to outsource more of their development and manufacturing processes, creating new opportunities for CDMOs. What Are the Key Segments of the CDMO Market?Service types include contract development (drug discovery, preclinical and clinical development) and contract manufacturing (small molecule production, biologics manufacturing). CDMOs serve various segments, including pharmaceuticals, biotechnology, and medical device companies. The demand for biologics and biosimilars is driving significant growth in the CDMO market, particularly for services related to monoclonal antibody production, cell and gene therapy, and vaccine manufacturing. The rise of personalized medicine is also contributing to the expansion of the CDMO market, as it requires flexible manufacturing capabilities to produce customized Are Technological Advancements Driving Innovation in CDMOs?Technological innovations are enhancing the capabilities of CDMOs, particularly in the areas of biologics manufacturing and continuous production. Advances in bioprocessing technologies, such as single-use systems and modular production facilities, are enabling CDMOs to scale up production more efficiently and with greater flexibility. Continuous manufacturing technologies, which allow for the uninterrupted production of pharmaceuticals, are also gaining traction in the CDMO sector, reducing production costs and improving product quality. Additionally, the integration of digital technologies, such as data analytics and automation, is enabling CDMOs to optimize production processes, ensure compliance with regulatory standards, and reduce the risk of human ScopeKey Insights: Market Growth: Understand the significant growth trajectory of the Contract Manufacturing segment, which is expected to reach US$425.9 Billion by 2030 with a CAGR of a 8.1%. The Contract Development segment is also set to grow at 6.0% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $97.9 Billion in 2024, and China, forecasted to grow at an impressive 7.1% CAGR to reach $84.0 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Albany Molecular Research, Inc., Catalent, Inc., Covance, Inc., DPT Laboratories Ltd., Flex and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Tariff Impact Analysis: Key Insights for 2025What's Included in This Edition: Tariff-adjusted market forecasts by region and segment Analysis of cost and supply chain implications by sourcing and trade exposure Strategic insights into geographic shifts Buyers receive a free July 2025 update with: Finalized tariff impacts and new trade agreement effects Updated projections reflecting global sourcing and cost shifts Expanded country-specific coverage across the industry Key Attributes: Report Attribute Details No. of Pages 89 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $351.7 Billion Forecasted Market Value (USD) by 2030 $547.1 Billion Compound Annual Growth Rate 7.6% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights Tariff Impact on Global Supply Chain Patterns Global Economic Update Healthcare Contract Development and Manufacturing Organization - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Rising Outsourcing of Pharmaceutical and Biotech Manufacturing Drives Growth in Healthcare CDMO Market Growing Demand for Biologics and Biosimilars Propels Market Opportunities for CDMOs Increasing Focus on Speed-to-Market for Drug Development Strengthens Business Case for CDMOs Technological Advancements in Bioprocessing and Cell Therapy Manufacturing Drives Adoption of CDMO Services Expansion of Personalized Medicine and Gene Therapies Fuels Growth in the CDMO Sector Rising Pharmaceutical R&D Expenditure Expands Addressable Market for CDMOs Increasing Demand for Flexible Manufacturing and Modular Production Solutions Expands Market Opportunities Technological Innovations in Continuous Manufacturing and Process Optimization Propel Market Growth Rising Outsourcing of Drug Discovery and Early-Stage Development Strengthens Market Demand Increasing Adoption of Single-Use Technologies in Biopharmaceutical Manufacturing Drives Growth in CDMO Market Rising Demand for Contract Manufacturing in Cell and Gene Therapy Expands CDMO Market Horizons FOCUS ON SELECT PLAYERS:Some of the 33 companies featured in this report Albany Molecular Research, Inc. Catalent, Inc. Covance, Inc. DPT Laboratories Ltd. Flex IQVIA Holdings, Inc. Jabil Lonza Group Ltd. Nextpharma Technologies Recipharm AB Sanmina Corporation Siegfried Holding AG Thermo Fisher Scientific, Inc. Unither Vetter For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Healthcare Contract Development and Manufacturing Organization Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-05-2025
- Business
- Yahoo
Healthcare CDMO Strategic Research Report 2025: Market to Surpass $350 Billion by 2030 - Rising Outsourcing of Drug Discovery and Early-Stage Development Strengthens Demand
This comprehensive report delves into market trends, drivers, and forecasts. Key growth areas include biologics manufacturing and personalized medicine, with significant contributions from technological advancements like continuous production and digital technologies. Regions like the U.S. and China showcase robust growth, emphasizing the critical role of CDMOs in drug development and manufacturing. Healthcare Contract Development and Manufacturing Organization Market Dublin, May 27, 2025 (GLOBE NEWSWIRE) -- The "Healthcare Contract Development and Manufacturing Organization - Global Strategic Business Report" report has been added to global market for Healthcare Contract Development and Manufacturing Organization was valued at US$351.7 Billion in 2024 and is projected to reach US$547.1 Billion by 2030, growing at a CAGR of 7.6% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Healthcare Contract Development and Manufacturing Organization market. Healthcare Contract Development and Manufacturing Organizations (CDMOs) are critical partners in the pharmaceutical and biotechnology industries, providing outsourced services for drug development, manufacturing, and commercialization. CDMOs offer a range of services, from early-stage drug discovery and development to clinical trials and commercial-scale production. By outsourcing to CDMOs, pharmaceutical companies can reduce costs, accelerate time-to-market, and focus on core competencies such as research and marketing. The rise of biologics, biosimilars, and personalized medicine has further expanded the role of CDMOs, as these complex therapies require specialized manufacturing expertise that many pharmaceutical companies lack in-house. What Factors Are Driving the Growth in the Healthcare CDMO Market?The growth in the healthcare CDMO market is driven by several factors, including the increasing outsourcing of drug development and manufacturing activities by pharmaceutical and biotechnology companies. The rising demand for biologics, biosimilars, and personalized medicine is fueling the need for specialized manufacturing capabilities that CDMOs provide. Additionally, the need for faster time-to-market and cost-effective production solutions is pushing pharmaceutical companies to partner with CDMOs. Technological advancements in bioprocessing and continuous manufacturing are further driving the growth of the CDMO market. Furthermore, regulatory pressures and the complexity of drug development are encouraging pharmaceutical companies to outsource more of their development and manufacturing processes, creating new opportunities for CDMOs. What Are the Key Segments of the CDMO Market?Service types include contract development (drug discovery, preclinical and clinical development) and contract manufacturing (small molecule production, biologics manufacturing). CDMOs serve various segments, including pharmaceuticals, biotechnology, and medical device companies. The demand for biologics and biosimilars is driving significant growth in the CDMO market, particularly for services related to monoclonal antibody production, cell and gene therapy, and vaccine manufacturing. The rise of personalized medicine is also contributing to the expansion of the CDMO market, as it requires flexible manufacturing capabilities to produce customized Are Technological Advancements Driving Innovation in CDMOs?Technological innovations are enhancing the capabilities of CDMOs, particularly in the areas of biologics manufacturing and continuous production. Advances in bioprocessing technologies, such as single-use systems and modular production facilities, are enabling CDMOs to scale up production more efficiently and with greater flexibility. Continuous manufacturing technologies, which allow for the uninterrupted production of pharmaceuticals, are also gaining traction in the CDMO sector, reducing production costs and improving product quality. Additionally, the integration of digital technologies, such as data analytics and automation, is enabling CDMOs to optimize production processes, ensure compliance with regulatory standards, and reduce the risk of human ScopeKey Insights: Market Growth: Understand the significant growth trajectory of the Contract Manufacturing segment, which is expected to reach US$425.9 Billion by 2030 with a CAGR of a 8.1%. The Contract Development segment is also set to grow at 6.0% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $97.9 Billion in 2024, and China, forecasted to grow at an impressive 7.1% CAGR to reach $84.0 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Albany Molecular Research, Inc., Catalent, Inc., Covance, Inc., DPT Laboratories Ltd., Flex and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Tariff Impact Analysis: Key Insights for 2025What's Included in This Edition: Tariff-adjusted market forecasts by region and segment Analysis of cost and supply chain implications by sourcing and trade exposure Strategic insights into geographic shifts Buyers receive a free July 2025 update with: Finalized tariff impacts and new trade agreement effects Updated projections reflecting global sourcing and cost shifts Expanded country-specific coverage across the industry Key Attributes: Report Attribute Details No. of Pages 89 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $351.7 Billion Forecasted Market Value (USD) by 2030 $547.1 Billion Compound Annual Growth Rate 7.6% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights Tariff Impact on Global Supply Chain Patterns Global Economic Update Healthcare Contract Development and Manufacturing Organization - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Rising Outsourcing of Pharmaceutical and Biotech Manufacturing Drives Growth in Healthcare CDMO Market Growing Demand for Biologics and Biosimilars Propels Market Opportunities for CDMOs Increasing Focus on Speed-to-Market for Drug Development Strengthens Business Case for CDMOs Technological Advancements in Bioprocessing and Cell Therapy Manufacturing Drives Adoption of CDMO Services Expansion of Personalized Medicine and Gene Therapies Fuels Growth in the CDMO Sector Rising Pharmaceutical R&D Expenditure Expands Addressable Market for CDMOs Increasing Demand for Flexible Manufacturing and Modular Production Solutions Expands Market Opportunities Technological Innovations in Continuous Manufacturing and Process Optimization Propel Market Growth Rising Outsourcing of Drug Discovery and Early-Stage Development Strengthens Market Demand Increasing Adoption of Single-Use Technologies in Biopharmaceutical Manufacturing Drives Growth in CDMO Market Rising Demand for Contract Manufacturing in Cell and Gene Therapy Expands CDMO Market Horizons FOCUS ON SELECT PLAYERS:Some of the 33 companies featured in this report Albany Molecular Research, Inc. Catalent, Inc. Covance, Inc. DPT Laboratories Ltd. Flex IQVIA Holdings, Inc. Jabil Lonza Group Ltd. Nextpharma Technologies Recipharm AB Sanmina Corporation Siegfried Holding AG Thermo Fisher Scientific, Inc. Unither Vetter For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Healthcare Contract Development and Manufacturing Organization Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
24-05-2025
- Business
- Time of India
China's India Headache: The growing pharmaceutical industry
When the world sneezes from a US-China chill, Indian companies rush to make medicines. Literally. Sometime in April, Vivek Sharma, executive chairman of Suven Pharmaceuticals , was on a trans-continental call with the top officials of a tech-driven global pharmaceutical ingredients company, for a potential deal. It could possibly be a future asset for the Hyderabad-based firm that is evaluating high-end, specialised platforms in a bid to bulk up its technological prowess and grab manufacturing mandates from pharma and biotech giants in the West. Before that, in December, Suven acquired a controlling stake in NJ Bio Inc, a contract research organisation based in Princeton, US, that focuses on antibody-drug conjugates, a targeted therapy for cancer. The $65 million acquisition has positioned Suven as a key player in the market of contract development and manufacturing organisations or CDMOs. These are third-party companies that provide a range of services to global pharma—from early-stage re - search to regulatory submissions to the manufacturing of the latest drugs. Suven is one among a host of Indian CDMOs like Aurigene, Sai Life Sciences, and Syngene International , which are prepping for the next phase of growth and expansion through strategic mergers and acquisitions abroad amid a rising call from global pharma companies to nearshore projects in US and Europe. 'We remain focused on building a technology-led global CDMO platform. Our acquisition strategy is around assets that bring in cutting-edge technology and strong scientific talent,' says Sharma. Meanwhile, Biocon company Syngene International has just completed its acquisition of Emergent BioSolutions , a biologics-manufacturing facility in Baltimore, US. Biologics are medications that come from living organisms, like proteins and genes. The $36.5 million deal gives Syngene 'a strategic foothold in the US by bringing it closer to the wider customer market,' says Peter Bains, MD and CEO, Syngene International. Several Indian CDMOs, which have been helping drive the innovation engines of large pharmaceutical companies in the West, are scouting for suitable assets in the US and Europe to fast-track their capacity building. 'The business development guys of almost every CDMO in India are out there on the US East Coast and some parts of the West Coast, evaluating possible acquisition targets,' says a top industry official. While the Indian facilities of these companies have been helping global drug makers for years, they are now exploring strategic acquisitions in specialised, high-growth therapeutic areas such as biologics, cell and gene therapy and oncology. 'What we are looking for are enhanced capabilities—particularly in research and complex chemistry. The idea is to establish highly specialised labs where our scientists co-create solutions alongside innovator partners,' says Sharma. However, 'India will remain our hub for commercial-scale manufacturing, where we continue to enjoy a global cost advantage.' NEARSHORING & GLOBAL PHARMA Nearshoring and reshoring are gaining momentum among global pharma majors that are looking to mitigate risks posed by supply chain disruption and rising offshore cost. According to a report by consulting firm LoEstro, pharma companies in the West are investing in local and regional facilities to reduce supply chain risks, ensure regulatory compliance and enhance production resilience amid global disruptions. Siva Chittor, CFO of Sai Life Sciences, says, 'We are seeing a growing customer preference for nearshoring.' Sai has been an early mover in this space, establishing R&D labs in US and UK about five years ago. 'These labs allow us to be closer to our customers,' he adds. A key driver is the increasing trend of global customers looking to re-balance their supply chains from China. Multinational pharma companies in US and Europe want to diversify their manufacturing bases in a bid to reduce their over-reliance on China amid geopolitical uncertainties and a growing divide between Washington and Beijing. However, such is the dependence on China, that US's proposed BioSecure Act , which seeks to restrict American companies from doing business with Chinese drugmakers, has been put on the backburner. If US puts hurdles for Chinese pharma companies, it will create huge opportunities for India. Indian CDMOs, which have a significant presence in small-molecule manufacturing, are now stepping up into biologics, which are large complex molecules, and advanced therapeutic modalities that can help them snatch a large slice of the pie from Chinese manufacturers. 'The Indian CDMO sector is well poised for growth to capitalise on the changing global dynamics,' says Akhil Ravi, CEO of Bengaluru-headquartered Aurigene Pharmaceutical Services. 'Factors such as robust infrastructure, regulatory compliance and highly skilled talent pool have strengthened India's position to become a preferred strategic partner for global companies in drug development. We remain committed to expanding our capabilities and capacity to meet rising demand in small-molecule APIs (active pharma - ceutical ingredients), peptides and bio - logics,' says Ravi. Peptides are smaller forms of proteins. Says Bains of Syngene: 'India is entering a critical phase in the evolution of its CDMO industry. A CAGR of 15% in 2019- 24, double the global growth rate of 7-8%, indicates that there are strong tailwinds for India.' At Syngene, the conversations with its customers are around its end-to-end ability to strategically support them in R&D and manufacturing and its long-term sup - ply chain resilience. 'We are seeing in - creased visits by both large and mid-sized pharma companies, which are running comparative pilots with a few organisa - tions as a way of selecting longer-term partners. We have been successful in con - verting a majority of these pilots into fulltime contracts,' says Bains. Deepak Jain, MD and CEO of Jubilant Ingrevia, which has partnered with glob - al drug firms for manufacturing drug intermediates, expects 6-7x growth in pharma contracts over the next few years. 'This is a golden opportunity for India. If not India, who else?' he asks. Inorganic expansion, through acquisi - tions abroad, enables Indian companies to stave off the threat of tariffs and geo - political impact and access highly skilled manpower, says Sujay Shetty, global health industries advisory leader, PwC. 'Also, from the IP perspective, it makes more sense if they are on the ground there since they will be running highly confidential projects for clients that could be multinational innovator companies or biotech companies,' he adds. Piramal Pharma, which recently announced a capex of $90 million for the expansion of two of its US facilities in Kentucky and Michigan, will focus on organic, brownfield expansion in the drug development and manufacturing service business, says chairperson Nandini Piramal. The company has four manufacturing facilities in North America and two in the UK. 'We are one of the best-positioned CDMOs to benefit from pharma companies wanting to onshore manufacturing in US,' says Piramal. The overseas facilities of Indian companies will be mostly in advanced therapeutic segments. Says Annaswamy Vaidheesh, former MD of GSK Pharma India: 'Their strategic priorities are in - creasingly aligned with high-value segments such as biologics and advanced technology platforms that require differentiated capabilities and offer greater margin potential.' Biologics require specialised facilities and expertise that drive up production cost but can generate higher profit margin. However, Vaidheesh warns that establishing a fully onshore, end-to-end sup - ply chain for US clients through Indian partners will take time, as it involves scaling capabilities and aligning regulatory and operational processes. 'Innovators typically assess whether a CDMO has the bandwidth to take on new programmes. Without demonstrable ca - pacity, even strong technical competen - cies may not suffice,' says Vaidheesh. Key Indian companies have been in - vesting heavily to enhance capacity. Aurigene has made significant additions to its infrastructure and established a new biologics facility at Genome Valley, Hyderabad. Chinese companies have been the preferred CDMO partner for US companies —grabbing 80% market share—because they are good in speed and low in cost. India is well-positioned to play a greater role in global supply chains, but the pace and quality of transition will depend on several factors. Speed of execution has been a major pain point for Indian CDMOs, which have to go through multiple levels of domestic regulatory approvals that delay consignments to customers by three-four months. 'Speed and agility are key expectations from global innovators. Chinese CDMOs have set high benchmarks in terms of responsiveness. Indian players need to invest in systems and capabilities that allow them to meet these expectations competitively,' says Vaidheesh. RISING PE INTEREST Rising growth opportunities and the China+1 plan of MNCs have led to sustained investor interest in the Indian CDMO space. Over $900 million has come from private investments and nearly $750 million has been raised through IPOs over the past 15 months, according to Grant Thornton. 'This reflects the segment's growing strategic relevance, driven by global demand for outsourced development and manufacturing and India's established expertise in generics, APIs and complex formulations,' says Bhanu Prakash Kalmath SJ, partner and healthcare industry leader. Another significant development has been US President Donald Trump's executive order that directed drug companies to reduce the prices of medicines in 30 days. While that could still see negotiations, some experts suggest the direct result will be companies' looking at partners in India to cut their costs of research and production. This seems like a shot in the arm for Indian CDMOs. Can they now make a dent in the time-tested Chinese pharma supply chain? The results are awaited .
